With the FDA approval of Bydureon in January 2012, there will be three injectable GLP-1 agonists available for the treatment of Type 2 Diabetes.
The battle of the GLP-1's will shortly be in full swing.
Each of the injectable GLP-1 agonists (Byetta, Victoza and Bydureon) are incretin-based therapies.
Incretins are hormones that are released by the gut in response to a sugar load from a meal.
Once released, the incretins stimulate insulin secretion, reduce glucagon secretion, and slow the transit of food in your gut.
The battle of the GLP-1's will shortly be in full swing.
Each of the injectable GLP-1 agonists (Byetta, Victoza and Bydureon) are incretin-based therapies.
Incretins are hormones that are released by the gut in response to a sugar load from a meal.
Once released, the incretins stimulate insulin secretion, reduce glucagon secretion, and slow the transit of food in your gut.
